Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitravatinib - Mirati Therapeutics

Drug Profile

Sitravatinib - Mirati Therapeutics

Alternative Names: IND-155305; MG-516; MG91516; MGCD-0516; MGCD-516; Sitravatinib-malate; Sitravatinib-malate-Mirati-Therapeutics

Latest Information Update: 02 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Developer BeiGene; Cancer Research UK; Columbia University; Fudan University; Mirati Therapeutics; University Health Network; University of Birmingham
  • Class Amides; Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorobenzenes; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; Proto-oncogene protein c-ret inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE-2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase II/III Solid tumours
  • Phase II Cholangiocarcinoma; Liposarcoma; Oesophageal cancer; Soft tissue sarcoma; Squamous cell cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Gastric cancer; Liver cancer

Most Recent Events

  • 22 Apr 2024 Mirati Therapeutics terminates a phase-II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) due to sponsor portfolio reprioritisation as of April 2024 (NCT02954991)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (PO)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top